Silverfin false false 31/08/2025 01/09/2024 31/08/2025 R Marais 30/09/2022 P J Masterson 17/10/2023 C Springer 02/08/2021 13 April 2026 no description of principal activity 13542017 2025-08-31 13542017 bus:Director1 2025-08-31 13542017 bus:Director2 2025-08-31 13542017 bus:Director3 2025-08-31 13542017 2024-08-31 13542017 core:CurrentFinancialInstruments 2025-08-31 13542017 core:CurrentFinancialInstruments 2024-08-31 13542017 core:Non-currentFinancialInstruments 2025-08-31 13542017 core:Non-currentFinancialInstruments 2024-08-31 13542017 core:ShareCapital 2025-08-31 13542017 core:ShareCapital 2024-08-31 13542017 core:RetainedEarningsAccumulatedLosses 2025-08-31 13542017 core:RetainedEarningsAccumulatedLosses 2024-08-31 13542017 core:PlantMachinery 2024-08-31 13542017 core:OfficeEquipment 2024-08-31 13542017 core:PlantMachinery 2025-08-31 13542017 core:OfficeEquipment 2025-08-31 13542017 bus:OrdinaryShareClass1 2025-08-31 13542017 2024-09-01 2025-08-31 13542017 bus:FilletedAccounts 2024-09-01 2025-08-31 13542017 bus:SmallEntities 2024-09-01 2025-08-31 13542017 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 13542017 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 13542017 bus:Director1 2024-09-01 2025-08-31 13542017 bus:Director2 2024-09-01 2025-08-31 13542017 bus:Director3 2024-09-01 2025-08-31 13542017 core:PlantMachinery core:TopRangeValue 2024-09-01 2025-08-31 13542017 core:OfficeEquipment core:TopRangeValue 2024-09-01 2025-08-31 13542017 2023-09-01 2024-08-31 13542017 core:PlantMachinery 2024-09-01 2025-08-31 13542017 core:OfficeEquipment 2024-09-01 2025-08-31 13542017 core:Non-currentFinancialInstruments 2024-09-01 2025-08-31 13542017 bus:OrdinaryShareClass1 2024-09-01 2025-08-31 13542017 bus:OrdinaryShareClass1 2023-09-01 2024-08-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 13542017 (England and Wales)

# ONCODRUG LTD

### Unaudited Financial Statements
For the financial year ended 31 August 2025
Pages for filing with the registrar

ONCODRUG LTD

## Unaudited Financial Statements

For the financial year ended 31 August 2025

Contents

ONCODRUG LTD

## COMPANY INFORMATION

For the financial year ended 31 August 2025
ONCODRUG LTD

## COMPANY INFORMATION (continued)

For the financial year ended 31 August 2025

Directors | R Marais
| P J Masterson
| C Springer

Registered office | The Heath Business And Technical Park
| Runcorn
| WA7 4QX
| United Kingdom

Company number | 13542017 (England and Wales)

Accountant | Kreston Reeves LLP
| Suite 2
| Orchard House
| Orchard Street
| Canterbury
| Kent
| CT2 8AR

ONCODRUG LTD

## BALANCE SHEET

As at 31 August 2025
ONCODRUG LTD

## BALANCE SHEET (continued)

As at 31 August 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 3 | 98,304 |  | 95,681
|  | 98,304 |  | 95,681
Current assets |  |  |  |
Debtors | 4 | 975,231 |  | 306,984
Cash at bank and in hand |  | 1,820,037 |  | 3,835,563
|  | 2,795,268 |  | 4,142,547
Creditors: amounts falling due within one year | 5 | ( 119,170) |  | ( 471,300)
Net current assets |  | 2,676,098 |  | 3,671,247
Total assets less current liabilities |  | 2,774,402 |  | 3,766,928
Creditors: amounts falling due after more than one year | 6 | ( 1,100,000) |  | ( 1,100,000)
Net assets |  | 1,674,402 |  | 2,666,928
Capital and reserves |  |  |  |
Called-up share capital | 7 | 211 |  | 211
Profit and loss account |  | 1,674,191 |  | 2,666,717
Total shareholders' funds |  | 1,674,402 |  | 2,666,928

For the financial year ending 31 August 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Oncodrug Ltd (registered number: 13542017) were approved and authorised for issue by the Board of Directors on 13 April 2026. They were signed on its behalf by:

C Springer Director |

ONCODRUG LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 August 2025
ONCODRUG LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 August 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Oncodrug Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is The Heath Business And Technical Park, Runcorn, WA7 4QX, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.
Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

##### Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

##### Finance costs

Finance costs are charged to the Profit and Loss Account over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery | 5 years straight line
Office equipment | 5 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Borrowing costs

Borrowing costs that are directly attributable to acquisition, construction or production of qualifying assets, are capitalised as part of the cost of those assets. Capitalisation begins when both finance costs and expenditures for the asset are being incurred and activities that are necessary to get the asset ready for use are in progress. Capitalisation ceases when substantially all the activities that are necessary to get the asset ready for use are complete.
All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

##### Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Profit and Loss Account over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

##### Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate
probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 16 |  | 18

#### 3. Tangible assets

| Plant and machinery |  | Office equipment |  | Total
| £ |  | £ |  | £
Cost |  |  |  |  |
At 01 September 2024 | 0 |  | 136,724 |  | 136,724
Additions | 32,542 |  | 2,371 |  | 34,913
At 31 August 2025 | 32,542 |  | 139,095 |  | 171,637
Accumulated depreciation |  |  |  |  |
At 01 September 2024 | 0 |  | 41,043 |  | 41,043
Charge for the financial year | 4,865 |  | 27,425 |  | 32,290
At 31 August 2025 | 4,865 |  | 68,468 |  | 73,333
Net book value |  |  |  |  |
At 31 August 2025 | 27,677 |  | 70,627 |  | 98,304
At 31 August 2024 | 0 |  | 95,681 |  | 95,681

#### 4. Debtors

| 2025 |  | 2024
| £ |  | £
Trade debtors | 129,107 |  | 0
Prepayments and accrued income | 211,160 |  | 231,892
VAT recoverable | 66,018 |  | 0
Corporation tax | 485,607 |  | 0
Other debtors | 83,339 |  | 75,092
| 975,231 |  | 306,984

#### 5. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Trade creditors | 104,184 |  | 59,764
Accruals | 12,000 |  | 32,260
Corporation tax | 0 |  | 351,256
Other taxation and social security | 0 |  | 16,581
Other creditors | 2,986 |  | 11,439
| 119,170 |  | 471,300

#### 6. Creditors: amounts falling due after more than one year

| 2025 |  | 2024
| £ |  | £
Other creditors | 1,100,000 |  | 1,100,000

Funds were paid under a simple agreement for future equity agreement but they are shown as a liability because the number of shares to be purchased is uncertain at this point.

#### 7. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
211,000 Ordinary shares of £ 0.001 each | 211 |  | 211

#### 8. Ultimate controlling party

In the opinion of the directors there is no controlling party.